Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche achieved a sales growth of 7% (3% in CHF ... significant and clinically meaningful two years after treatment with Elevidys, compared to a pre-specified propensity-weighted untreated external ...

The result comes a few months after the only FDA-approved gene therapy for DMD – Roche/Sarepta’s Elevidys (delandistrogene moxeparvovec) – failed to meet its primary objective in a phase 3 ...

Sarepta hasn’t yet given any indication of its sales expectations for Elevidys this year, but more information may be forthcoming on a conference call with analysts later today. Roche gets the ...

Their advice comes from personal experience. After entering into many tough conversations about money among themselves, friends and others, they buckled down and paid off $200,000 in debt, learned ...

Check Out Our Latest Stock Analysis on Sarepta Therapeutics Sarepta Therapeutics Stock Down 0.6 % Shares of NASDAQ:SRPT opened at $113.72 on Thursday. Sarepta Therapeutics has a 1 year low of $102 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.

aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil bGrupo de Pesquisa Clínica em Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil ...